-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Celldex Therapeutics, Raises Price Target to $64

Benzinga·09/22/2026 16:13:07
HC Wainwright & Co. analyst Joseph Pantginis maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and raises the price target from $42 to $64.